The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives
Author:
- 1 October 2011
- journal article
- review article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 205 (4) , S9-S13
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiolThe European Journal of Contraception & Reproductive Health Care, 2010
- Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogestExpert Opinion on Pharmacotherapy, 2010
- Perceptions of the safety of oral contraceptives among a predominantly Latina population in TexasContraception, 2010
- Hormonal ContraceptionObstetrics & Gynecology, 2008
- Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception studyBMJ, 2007
- Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral ContraceptivesObstetrics & Gynecology, 2007
- Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System UsersObstetrics & Gynecology, 2007
- The emerging use of the 20-μg oral contraceptiveFertility and Sterility, 2001
- Pharmacokinetics of Etonogestrel and Ethinylestradiol Released from a Combined Contraceptive Vaginal RingClinical Pharmacokinetics, 2000
- Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activityFertility and Sterility, 1999